Found 7 matching trials
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
PHASE2This is a randomized non-comparative, multicenter phase II study in patient...
Location
Institut de Cancerologie de L'Ouest Paul Papin
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
PHASE1This phase I trial tests the safety and effectiveness of nivolumab and ipil...
Location
City of Hope Medical Center
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
PHASE1Clostridioides difficile infection (CDI) is the leading cause of nosocomial...
Location
CH Annecy Genevois Service de Maladies infectieuses
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
PHASE1As treatment options are limited following progression on anti PD-(L)1 and ...
Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
PHASE2MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, mu...
Location
CHU Clermont-Ferrand
EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
PHASE1A Phase 1, 2-part, multicentre study to evaluate the safety and preliminary...
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
PHASE2Hepatocellular carcinoma (HCC) is the most common liver primary cancer with...